Procaps is a leading integrated LatAm healthcare and pharmaceutical services company. However, the company faces significant near-term headwinds: in February 2025, Procaps received a delisting notice from Nasdaq due to failure to demonstrate compliance with listing rules for filing periodic and interim financial reports, resulting in the company's ordinary shares commencing trading on the OTC Expert Market on February 4, 2025.
Cyborg Score Rationale
Procaps operates a global pharmaceutical and nutraceutical platform across 50+ countries with a substantial regional footprint in the Americas. However, the company delayed filing of its 2023 annual report due to an ongoing internal investigation by its Audit Committee into matters involving historical accounting treatment and associated financials, and subsequently delisted from Nasdaq in February 2025 for non-compliance with filing requirements.
Top Insights
Nasdaq delisting (February 2025) due to filing delinquencies; now trades on OTC Expert Market
Ongoing internal investigation into historical accounting treatment initiated by Audit Committee
$130 million equity investment and ~$209 million debt restructuring completed with strategic leadership transition
Diversified product portfolio across OTC, prescription, supplements, and clinical solutions in 13 Americas countries
Named Competitors
Farmacosmética Colombia — Colombian pharmaceutical and cosmetic manufacturer